Mark N Stein
Mark N Stein
Scott Kopetz
Scott Kopetz
Eileen M O&#x;Reilly
Eileen M O&#x;Reilly
Clinical applications of PARP inhibitors in breast, ovarian, and prostate cancer: current insights and future directions [0.03%]
聚腺苷二磷酸核糖聚合酶抑制剂在乳腺癌、卵巢癌和前列腺癌中的临床应用：当前见解与未来方向
Laura M Linville,Jenna V Canzoniero,Catherine H Marshall et al.
Laura M Linville et al.
Poly(ADP-ribose) polymerase (PARP) inhibitors have emerged as an important therapeutic option for patients with homologous recombination repair (HRR)-deficient cancers, especially those with BRCA1/2 mutations. Since the initial US Food Admi...
Jason A Mouabbi,Marla D Lipsyc-Sharf,Fengting Yan
Jason A Mouabbi
Marla D Lipsyc-Sharf
Marla D Lipsyc-Sharf
Jason A Mouabbi
Jason A Mouabbi
Molecular residual disease (MRD) testing: advancing clinical decision-making in breast cancer [0.03%]
分子残留病灶（MRD）检测在乳腺癌临床决策中的应用进展
Jason A Mouabbi,Marla D Lipsyc-Sharf,Fengting Yan
Jason A Mouabbi
Circulating tumor DNA (ctDNA) is emerging as a clinically meaningful biomarker across multiple solid tumors, including breast cancer. Advances in personalized, tumor-informed whole-genome sequencing have enabled highly sensitive detection o...